Newsletter · · Ashutosh Agarwal

PBM Reform Bill Clears House Committee 40 to 2 - Drug Pricing & IRA Round 2 - Week of August 3, 2026

A synthesis of what health-policy and pharmacy podcasts said about drug pricing for the week of July 27 to August 3, 2026, including a federal PBM reform bill clearing a House committee 40 to 2, a firm timeline for the 100 percent generic tariff, and the full specification of Medicare's new GLP-1 pilot.

Drug Pricing & IRA Round 2

Week of July 27 to August 3, 2026: PBM Reform Bill Clears House Committee 40 to 2

TL;DR

  • The middleman finally got hit, a little. After years of hearings that went nowhere, a federal bill to rein in pharmacy-benefit managers (PBMs), the companies that sit between drugmakers and patients and decide which drugs get covered, actually cleared a House committee this week, on a lopsided 40-2 vote. Among other things it would ban PBMs from marking up drugs at pharmacies they own, kill retroactive fees, and raise the fine for breaking the rules from $10,000 to $1 million per violation. It's still years and several votes from becoming law, and it only covers federal-employee plans, but a PBM bill getting out of committee is genuinely rare. (Pharmacy Podcast Network)
  • The generic-tariff threat from last week grew teeth, and a clearer clock. On an Indian business podcast, the timeline got pinned down: a 100% tariff on imported generics from August 1, 2028, then 200% in 2029. Indian drugmakers, who supply roughly half of America's generic medicines and ship $8-9 billion of pharma to the US a year, reacted by mostly shrugging. Dr. Reddy's CEO said flatly the company won't relocate to dodge tariffs. The tell for a book: this raises the cost of the cheapest drugs and rewards whoever already has US plants. (Daybreak)
  • Medicare's new weight-loss drug program got real numbers. Last week we flagged that Medicare is, for the first time, covering GLP-1s (the Ozempic/Wegovy family) for weight loss. This week a former Kaiser Permanente CEO laid out the mechanics: a $50-a-month copay for patients, with the government paying about $245 a month, run as an 18-month pilot by Humana. Around 30 million of Medicare's 70 million members could qualify. Volume tailwind for Lilly and Novo, but it's a pilot that could vanish in a year and a half. (Fixing Healthcare Podcast)
  • A quiet Medicare subsidy is being pulled a year early. A temporary program that softened the blow of the IRA's new $2,000 out-of-pocket cap on stand-alone drug plans is being sunset in 2027 instead of running its full course. It cost taxpayers $9.8 billion over two years. The direct hit is small; the signal, that Washington is done cushioning insurers, is not.
  • Novo Nordisk lost about $15 billion of market value on a failed trial and reports earnings this coming Wednesday alongside Eli Lilly, the single most tradable event in this week's batch, even if it's about the pipeline, not pricing.

What's new

Ranked by how much a hedge-fund book can act on it.

1. PBM reform actually moved in Washington, the rarest kind of news in this space

For years, "PBM reform is coming" has been the drug-pricing equivalent of "this is the year of the Linux desktop." This week it took a real step. On a July 31 episode of the Pharmacy Podcast Network, two pharmacy advocates who'd just come back from Washington, an attorney closely involved in the bill and the show's host (both industry insiders, and both openly cheering it on), walked through what happened to HR 6610, the "Pharmacists Fight Back Act."

Plain-English version: a PBM is the company that employers and insurers hire to run their drug coverage. It decides which drugs are on the list ("the formulary"), negotiates prices, and, critically, often owns its own pharmacies and even, increasingly, its own drug operations. Three giants (CVS Caremark, Express Scripts, and Optum Rx) run most of the market. Critics say they profit from a black box no one can see into. This bill tries to pry the box open, at least for the federal-employee health program.

What actually happened, in the attorney's words:

"They held a markup… in essence, we've moved the bill out of the house committee… It's got to make it through the committee of jurisdiction before it could be considered in a larger package or as a standalone bill… It's frankly very, very rare."

The bill would hit PBMs on "reimbursement, in terms of steering, in terms of ending the ability for PBMs to massively mark up medications at pharmacies that they own… prohibiting retroactive fees." And in one respect it got tougher on its way through committee: the penalty for a violation jumped from "a $10,000 fine per violation… to one million dollars." The one concession: it now takes effect in two years instead of one. The committee vote was 40 to 2, "one Republican and one Democrat voting no," with Rep. James Comer, the Kentucky congressman who chairs the Oversight Committee, as the key champion. The episode also flagged Senator Warren using an Armed Services subcommittee to spotlight "Express Scripts practices in the TRICARE pharmacy program."

A note on the state of play, because two of this week's podcasts don't quite agree. On a July 27 Business Group on Health episode, Rachel Sachs, a law professor who worked in the Biden administration implementing the IRA's Medicare drug-pricing reforms, described "PBM reform" as something that "recently became law," as part of a broader bipartisan push, while stressing it "alone does not solve the whole problem." That's a looser characterization than the Pharmacy Podcast Network's blow-by-blow, which describes HR 6610 as having only cleared committee, not become law. The honest read: there is real, multi-front momentum on PBMs, but the specific federal bill everyone's excited about is still a bill, not a statute. Don't model a CVS/Cigna/UNH earnings hit off a committee vote. Do treat it as the clearest sign yet that the PBM profit pool is a political target with teeth forming. (Business Group on Health)

Why it matters for a book: the PBMs are inside CVS Health, Cigna (Express Scripts), and UnitedHealth (Optum). The three biggest read-throughs in this letter all run through this profit pool. A rule that bans marking up your own pharmacy and slaps $1 million fines on violations is the kind of thing that, if it ever becomes law, re-rates a regulated spread. It isn't law. But it's moving.

2. The generic-drug tariff gets a clock, and the targets say "we're not moving"

Last week's new item was President Trump's threat of a 100% (rising to 200%) tariff on generic drugmakers who don't move production to the US. This week we got the sequel: how the industry actually plans to respond. It came from Daybreak, a business podcast from the Indian outlet The Ken, hosted by journalists Rachel Varghese and Nikita Sharma, who relay a lot of operator and analyst voices. The episode title says it all: "Why Indian pharma isn't scared of a 100% tariff (yet)."

The specifics, which sharpen last week's fuzzier picture:

  • The clock. Countries like India get a "two-year window before a 100% tariff kicks in on August 1st of 2028. And then, if they haven't shifted some of the manufacturing to the US by 2028, then a 200% tariff will take effect in 2029." (Worth noting: the 200% escalation lands after Trump's current term ends, "and no one knows if the succeeding government will follow through with it.")
  • Why it matters so much. India supplies "nearly 50% of all generic medicines consumed in America," and "exports close to $8 to $9 billion worth of pharmaceutical products to the US every year, and the vast majority of it is generics." Indian pharma stocks fell on the news, the Nifty Pharma index off more than 1%, Sun Pharma nearly 1%, Cipla almost 2%.
  • The paradox at the center. Generics "account for 90% of all prescriptions in the US" but "contribute only to 13% of drug spending" (per the head of India's pharma export council). So the tariff aims at the cheap, high-volume, thin-margin end, the opposite of a pricing-power story.
  • The likely result if it bites. A study in Health Affairs Scholar estimated a worldwide 100% tariff would push US generic prices up about 30%, roughly $21 on a $70 average prescription, hitting everyday drugs like "birth control, antidepressants, and hypertension treatments," categories where India supplied more than half of 2024 prescriptions.

Here's the operator voice that matters most. Dr. Reddy's CEO Erez Israeli said the company has no plans to relocate manufacturing to the US: "we are not going to invest because of tariffs. We are going to invest because it's good business." The reasons, echoed by analysts at Nuvama, Motilal Oswal, and Teneo: building a US generics plant takes "at least five years," not two; US manufacturing costs would erase already-thin margins (India is "40-60% lower"); and, the deepest problem, moving the final step to the US doesn't fix the fact that China controls the key starting chemicals for "94% of amoxicillin, 74% of heparin, and 70% of acetaminophen." India itself imports "nearly 70%" of its chemical APIs from China.

The actionable twist, there are relative winners. The podcast named companies "already positioned to profit from the very tariff that everyone else is bracing for," because they already have US capacity:

  • Aurobindo Pharma, a "500,000 square feet" New Jersey campus, and it "just acquired Lannett," which brings an Indiana plant that "can scale to produce roughly 4 billion doses in a year."
  • Senores Pharmaceuticals, whose US-approved portfolio "doubled from 26 products to 51 in just a year," which bought a majority stake in a US plant, and formed a joint venture aimed at "federal and veterans affairs contracts."
  • Sun Pharma, Dr. Reddy's, and Cipla already have US plants; Cipla is expanding in Massachusetts and New York. (North America is about a third of Dr. Reddy's revenue and ~22% of Cipla's.)

For a book, the frame is the same as last week but with names attached: this is a supply-chain and cost story, not a pricing-power story, and "who already owns US plants" is the screen.

3. Medicare's weight-loss drug program: real numbers, real limits

Last week we noted Medicare quietly opening a door to weight-loss drugs. This week a former operator filled in the numbers. On a July 29 Fixing Healthcare Podcast, Dr. Robert Pearl, the former CEO of The Permanente Medical Group (Kaiser), and co-host Jeremy Corr walked through the new "BRIDGE" program:

  • "For the first time, Medicare will cover GLP-1 medications for weight loss," with a patient copay of "only $50 a month… about 80% less than the price that individuals who don't use their insurance pay" under the Trump-administration manufacturer agreement.
  • It's a pilot, capped at 18 months, because "Congress has prohibited medications for weight loss alone to be covered by Medicare." Running it as a CMS pilot is the workaround.
  • The government pays about "$245 a month" for the drugs.
  • It's run by Humana, and sits outside Part D, so the "$600 a year of out-of-pocket expenses… won't count toward their annual Part D deductible, nor to the $2,100 annual out-of-pocket drug coverage cap."
  • Eligibility ladders down with risk: BMI over 35 if otherwise healthy; over 30 with heart failure, uncontrolled blood pressure, or prediabetes; down to 27 for those with prior heart attacks, strokes, or peripheral vascular disease.
  • Patients get four choices: a weekly injectable, or a daily pill, Eli Lilly's Zepbound (injection) or its oral GLP-1 pill (called "Fandeo" on the podcast), or Novo Nordisk's Wegovy in injectable or pill form. Injectables average 15-20% weight loss; the pills 10-15%.
  • The size of the prize: of Medicare's ~70 million members, "around 40%, or close to 30 million individuals" appear to meet the criteria, though 16 million are already getting the drug through Part D for diabetes, heart disease or sleep apnea.

Pearl's caution is the part a book should underline: half of current enrollees "live on incomes of $43,000 a year," a quarter below $24,600, so even $600 a year "may prove prohibitive," and if the pilot's funding stops after 18 months, "enrollees are likely to regain the weight, and the pilot will have been a failure." Net: a real volume tailwind for the GLP-1 makers, but a fragile, temporary one.

4. A Medicare drug-plan subsidy gets yanked a year early, small dollars, loud signal

Two podcasts this week covered the same policy item: the Trump administration is ending, a year early, a temporary subsidy that cushioned stand-alone Medicare drug plans (PDPs) against the IRA's new $2,000 out-of-pocket cap.

The clearest explainer came from The Seven Figures Or Bust Podcast!, hosted by Medicare insurance agents Christian Brindle and Glenn Shelton, field operators who are opinionated and promotional but genuinely close to how these plans get priced and sold. Their walk-through:

  • The Part D Premium Stabilization Demonstration was introduced by the Biden administration for plan-year 2025, right as the IRA's $2,000 cap took effect, "to soften the blow" for insurers who otherwise would have jacked up premiums. It was a three-year program that shrank each year.
  • The numbers: in 2025, CMS paid carriers $15 a month per plan in exchange for capping premium increases; in 2026 that dropped to $10 a month. For 2027, "that'll be gone." Total taxpayer cost was "$9.8 billion" over 2025-2026, of which "$3.6 billion in 2026 alone."
  • The spin war. CMS Administrator Dr. Oz argues most beneficiaries will see premium increases "under $10 a month," pointing to TrumpRx, the new $50 GLP-1 program, and IRA-negotiated drug prices lowering carriers' costs. The agents are skeptical of the first two, "neither of those programs have anything to do with Part D," but concede the third is real: some "high-cost prescriptions that are really dragging down a lot of these Part D carriers… maybe those costs have been negotiated" down. They also note CMS "already has the bids from all these carriers," so the decision to pull the subsidy may reflect data the public can't see.

Their bottom line is refreshingly blunt: media claims that "Part D is ending" are nonsense, "it's a temporary subsidy that was already cut… it's just ending a year early," and the actual dollar impact is "a fraction of a percent" of the program.

The same episode surfaced a name-brand data point: on Humana's July 29 earnings call, CFO Celeste Mellett said the insurer plans additional Medicare Advantage market exits for 2027 that will "impact about 600,000 members," part of pushing toward its "2028 margin goals," versus roughly 2 million members terminated market-wide last year.

A more downbeat take on the same subsidy news came from the August 1 Health:Further episode, where healthcare commentators read it as "more bad news for… mid to lower-income families," expecting it to simply raise premiums: the administration and Dr. Oz "are spinning it" as unnecessary because drug costs have come down, but "it's going to bring more pressure, more pain in cost to consumers."

5. The rebate machine is quietly shifting, 26 products moved off the high-rebate model

For structural color on gross-to-net (the gap between a drug's list price and what's actually paid after rebates), a July 28 People Business w/ O'Brien McMahon episode with Matt Jarvis, PharmD, a pharmacist and PBM consultant talking his book somewhat, was the most number-dense of the week.

His clearest illustration used Humira: on a claims basis "most plans were probably paying $8,000 per script," got "$4,000 back in terms of a rebate… six months down the road," so net cost was $4,000, until a biosimilar (he cited Mark Cuban's low-cost version) showed up "at $800 per script." That gap is why plans are fleeing the rebate model. His headline data point: "even in 2026, we saw 26 products that manufacturers actually moved away from high cost, high rebate to low cost, no rebate. And we think that's going to double next year." He also pegged the scale of the hidden money, a plan spending "$1 million on drugs" typically generates "$400 to $500,000 of rebates," and confirmed the now-familiar figure that drug spend has gone from "5% of overall healthcare" to "35, 40% of every dollar that an employer spends."

One more small but interesting thread, from a July 29 Relentless Health Value episode with Ge Bai, PhD, CPA, a Johns Hopkins professor who, notably, was "recently nominated to be Assistant Secretary at the Department of Health and Human Services," so a critic turned insider. Host Stacey Richter mentioned spotting "legislation proposed to forbid this MFN, most favored nation, lesser-of language in PBM contracts." That's a different use of "most favored nation" than the Trump pricing orders. Here it refers to contract clauses that force pharmacies to give PBMs their lowest price, which the episode argues is what keeps cash list prices artificially high and creates the opening GoodRx monetizes. A niche point, but a reminder that "MFN" is now a live target in contract law, not just executive orders.

The debate

The core argument this letter tracks is unchanged, but this week added a second front (PBMs) and hardened the timeline on a third (generic tariffs).

"It's a series of bounded, manageable headwinds, and some of them even create volume." The bull case: the headline "Part D is ending" scare is false; the subsidy being pulled is "a fraction of a percent" of the program, and CMS pulled it because its own bid data suggested carriers no longer need it, possibly because IRA-negotiated prices are genuinely lowering drug costs. The generic tariff doesn't bite until August 2028, the industry says it can't and won't relocate, and the 200% escalation lands after this administration's term. Meanwhile Medicare just opened a $50-copay door to GLP-1s for ~30 million people, a rare positive-for-volume policy. And the PBM bill, however symbolically important, only cleared a committee and only covers federal employees. A well-capitalized company with US plants can navigate all of this.

"The squeeze is widening, and it's now hitting the cheap drugs and the middlemen at the same time." The bear reading: a 100%-to-200% tariff aimed at the thin-margin generic supply chain risks "higher prices and potential shortages" on the everyday drugs 90% of Americans fill, and the fix (US plants) is a five-year project that erases the margins that make generics cheap, while China still controls the underlying chemicals. On top of that, Washington is now cushioning insurers less (subsidy gone), squeezing the PBM profit pool more (a real bill, $1M fines, moving), and using pilots like BRIDGE to funnel more volume into the very GLP-1s that are the most obvious future price-negotiation targets. The subsidy withdrawal and Humana's planned 600,000-member exit are early evidence that the managed-care and Part D economics are getting harder, not easier.

The swing factor this week is PBM reform's odds. A committee vote is not a law, and this bill is FEHB-scoped. But if it becomes the template that gets attached to a larger package, as the advocates clearly hope, it's the first policy in this letter that directly threatens the CVS/Cigna/UNH profit engine rather than the drugmakers'. Watch whether HR 6610 gets folded into a bigger vehicle or dies on the House floor. And note the theme underneath both the tariff and the subsidy stories: the government is increasingly willing to let the pain land on someone, consumers, insurers, or importers, rather than keep absorbing it.

Stocks in play

Same straight talk as prior weeks: no podcast this week attached a franchise-level revenue-at-risk number to a tracked name. So this is only what the week's episodes actually implied.

Novo Nordisk (NVO), the week's most tradable single name.

  • Bear (near-term): Novo "sank" after a trial failure, with a "$15 billion dollar reduction in market cap" tied to a lost cardiovascular-pipeline opportunity, per Mizuho's Jared Holtz on CNBC's Fast Money. "There's no momentum in the short term in this name."
  • Bull (contrarian): the Fast Money traders argued the stock "gets no credit whatsoever for one of the most successful drug launches in history," the Wegovy pill, "a monster… one of the best we've ever seen." One trader: "if I hold this and look up a year or two from now, I will not regret that decision," calling it "compelling based on valuation" with "so much bad news baked in."
  • Next catalyst: Novo reports earnings this coming Wednesday, alongside Eli Lilly. Holtz is "pretty confident that Novo is going to have a good quarter," with the market watching for a possible "small guidance bump." (CNBC's "Fast Money")

Eli Lilly (LLY), the other half of Wednesday's GLP-1 double-header.

  • Bull: the BRIDGE program adds a covered Medicare channel for both Zepbound and Lilly's oral GLP-1 pill; the Street's obesity thesis has "shifted almost entirely to the pipeline, including retitrutide."
  • Bear/uncertainty: Holtz flagged that Lilly's oral GLP-1 "has been relatively disappointing," and he's "scratching his head" about retitrutide's market, "very incremental… I'm just not really sure we need it." Either it serves the very-high-BMI population or "it cannibalizes the existing sales."
  • Next catalyst: earnings Wednesday.

CVS Health (CVS), Cigna (CI), UnitedHealth (UNH), PBM read-through, indirect but real this week.

  • Bull: HR 6610 is FEHB-only, cleared just one committee, and won't take effect for two years even if it passes; the diversified insurers can adapt.
  • Bear: the PBM profit pool is now a live legislative target with $1M-per-violation teeth, and the "ban markups at your own pharmacy" provision goes straight at the vertically integrated model these three are built on. Add the early subsidy withdrawal and Humana's planned 600,000-member Medicare Advantage exit as evidence the managed-care and Part D setup is tightening.
  • Next to watch: whether HR 6610 gets attached to a larger package or stalls; 2027 bid and premium disclosures this fall.

Generic and API names (TEVA and Indian exporters: Sun Pharma, Dr. Reddy's, Cipla, Aurobindo, Senores), see Read-throughs; this is the week's sharpest supply-chain screen.

Read-throughs

Generic and biosimilar makers (TEVA; Indian exporters Sun Pharma, Dr. Reddy's, Cipla, Aurobindo, Senores). This is the week's most actionable screen. The tariff timeline is now explicit (100% from August 1, 2028; 200% in 2029), the targets have signaled they won't relocate ("we are not going to invest because of tariffs"), and the likely result is higher generic prices and shortage risk, not lower prices. The differentiator is existing US capacity: Aurobindo (New Jersey plus the Lannett/Indiana plant, ~4 billion doses/year) and Senores (US portfolio doubled to 51 products, federal/VA joint venture) were named as relative beneficiaries; Cipla is expanding in Massachusetts and New York. Pure importers with China-sourced APIs are the most exposed.

PBMs and managed care (CVS, CI, UNH). Two forces converged this week: a real reform bill advancing (HR 6610, $1M fines, ban on self-pharmacy markups) and a continuing narrative that the PBM model rests on opacity, Matt Jarvis's "$8,000 list / $4,000 rebate" Humira math, the "26 products moved off rebates in 2026, doubling next year" shift, and Ge Bai's account of how "most favored nation / lesser-of" contract clauses keep cash prices high. Meanwhile a PBM critic (Ge Bai) is heading into HHS leadership. None of this is an earnings shock yet, but the direction of travel, less protection for insurers, more scrutiny of the spread, is consistent and building.

Part D insurers and Medicare Advantage (Humana, CVS/Aetna, UNH, CI). The early sunset of the premium-stabilization subsidy removes a cushion right as the IRA's $2,000 cap fully bites, and CMS is signaling it's done propping up carriers. Humana's own CFO guiding to a 600,000-member Medicare Advantage exit for 2027 (toward "2028 margin goals") is the clearest company-level read that the math is tightening, even as the field operators argue the overall disruption is easing versus last year's ~2 million terminations. Watch the fall bid and premium disclosures.

GLP-1 volume vs. price (LLY, NVO, and Humana as administrator). BRIDGE is a genuine volume opener, up to ~30 million eligible, $50 copay, but it's an 18-month pilot the government is buying at ~$245/month, outside Part D, run by Humana. The tension remains the whole GLP-1 story: policy is adding covered volume to the exact drugs most likely to face future price negotiation and MFN pressure.

Small-molecule vs. biologic mix. Touched via Rachel Sachs: small-molecule generics can cut prices "80 to 90 percent or more" once FDA-approved and auto-substituted, while biosimilars "produce smaller discounts" and need insurers to cover and clinicians to prescribe them. It's a useful reminder of why the small-molecule "pill penalty" debate matters.

What changed vs. last week

Last week (July 21-27) was tariffs, insulin and plumbing: a Trump threat of a 100% generic tariff, a transparent-PBM founder describing the "black box," a Senate insulin-cap hearing, and the Humira patent-thicket history. This week was middlemen and clocks, genuinely more moved.

  • PBM reform stopped being just narrative and became a bill in motion. Last week we had a PBM founder venting about rebates; this week an actual federal bill (HR 6610) cleared a House committee 40-2, with penalties raised to $1 million per violation. That's a real, datable legislative milestone.
  • The generic tariff got a firm timeline and an industry answer. Last week's threat is now dated (100% from August 1, 2028; 200% in 2029) and met with a clear "we won't relocate" from Indian majors, plus named relative winners (Aurobindo, Senores, Cipla).
  • The GLP-1 "bridge" went from a one-line mention to a full spec: $50 copay, ~$245 government cost, 18-month pilot, Humana-run, outside Part D, ~30 million eligible.
  • A new policy item appeared: the early sunset (2027) of the Part D premium-stabilization subsidy, a $9.8B two-year program, with a named company data point in Humana's planned 600,000-member 2027 exit.
  • A tradable single-stock event: Novo's ~$15B market-cap drop on a failed trial, with Novo and Lilly both reporting Wednesday.